News in Brief

České Budějovice, 31st May – 2nd June 2023: 84. Kongres České́ společnosti Otorinolaryngologie a chirurgie hlavy a krku ČLS JEP   The Czech Society of Otorhinolaryngology and Head and Neck Surgery establishes recommended practices in the field and ensures...

Leipzig, 18-20th May 2023 - 94. Jahresversammlung der DGHNO-KHC, Congress Center Leipzig The German Society of Oto-Rhino-Laryngology, Head and Neck Surgery is dedicated to the advancement of scientific and clinical knowledge in its fields. AudioCure CEO, Reimar...

Dr. Michael Nieratschker from Allgemeines Krankenhaus Medical University of Vienna, Austria will present preclinical results about the effect of AC102 in a model of electrode insertion trauma at the ARO 2023 in Orlando. Moreover, Dr Reimar Schlingensiepen, CEO of AudioCure Pharma GmbH, will talk about the results of a Phase I clinical trial with AC102 in healthy volunteers.

At the start of the Phase II clinical trial, AudioCure Pharma GmbH will provide their newest insights on the mode of action of lead candidate AC102 at the 2nd Summit in Boston from 20-23 June 2022.

The FDA has granted orphan drug designation to AC102, concluding that AudioCure’s lead compound may become of significant benefit for patients suffering with the rare and chronically debilitating disease of sudden sensorineural hearing loss (SSNHL). Comprehensive...

The 3rd of March is World Hearing Day. On the occasion the World Health Organization (WHO) issued its first World Report on Hearing. Hearing disorders are known to be a global problem. The WHO however warns that by 2050 nearly 2.5 billion people will be living with some degree of hearing loss unless action is taken. In other words: In less than 30 years 1 in 4 people worldwide could be affected.

AudioCure Pharma GmbH, a pharmaceutical company based in Berlin, Germany, announced today that the first healthy volunteers have been included into the Phase I trial with the first-in-class molecule AC102. Main primary endpoints of the open-label study are safety and tolerability of AC102-suspension after injection into the middle ear.

AudioCure has made exciting progress in its preclinical program by extending both its indication and compound pipelines in recent months. We are very pleased to announce that we have therefore extended our scientific team to continue pushing our preclinical...

The EMA’s Committee for Orphan Medicinal Products has granted orphan drug designation to AC102, concluding that AudioCure’s lead compound may be of significant benefit for patients suffering with the rare and chronically debilitating disease of sudden sensorineural...

We are very happy to announce that we have expanded our team with further experts for formal preclinical and clinical development to propel our way into the clinical stage …